Related Experiment Video
Updated: Jul 8, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
[Determination concentrations of tissue factor pathway inhibitor and their changes during estrogen replacement
T Fait1, B Trnková, M Kostírova
1Gynekologicko-porodnická klinika VFN Praha a 1, LF UK, Praha. tfait@seznam.cz
Objective:
The purpose of the present study was to determine changes of tissue factor pathway inhibitor (TFPI) as a biochemical risk factors of thromboembolism during the use of different administration methods of the early estrogen replacement therapy.
Design:
Prospective randomized cross-over trial.
Setting:
General Faculty Hospital Prague.
Methods:
In a 12-week prospective, randomized, interventional, cross-over trial, estradiol was administered orally in a dose of 2 mg daily or transdermally in a dose of 0,05 mg daily. Forty-five healthy postmenopausal women were included into the study within 12 weeks after the hysterectomy and ovariectomy (surgical castration). Forty-one women completed the study and their data were analyzed. The average age was of 49 +/- 6 years. An enzymatic method (IMUBIND Total TFPI ELISA test) was employed for the determination of TFPI.
Results:
After the oral therapy, the average value of TFPI decreased statistically significantly (p < 0.0001) from 87.5 +/- 39.1 ng/ml to 68 +/- 37.49 ng/ml.
Conclusion:
Statistically the oral therapy reduced significantly TFPI compared with the transdermal method of administration. In spite of the fact that these changes cannot be unambiguously considered as risky and that the zero change of D-dimers suggests that there was no activation of the coagulation cascade, we consider the neutral effect of the transdermal therapy as more beneficial. The lack of manifestations of the coagulation cascade activation demonstrates the safety of both administration forms of the estrogen replacement therapy in the case of the early administration.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
01:19Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:22Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
01:31Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test